Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Additive Value of Pyridostigmine to Silodosin in the Management of Acute Urinary Retention Secondary to Benign Prostatic Hyperplasia

NCT06319469 is registered in ClinicalTrials.gov with Beni-Suef University as lead sponsor.

NCT NCT06319469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06319469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Additive Value of Pyridostigmine to Silodosin in the Management of Acute Urinary Retention Secondary to Benign Prostatic Hyperplasia
Lead sponsor
Beni-Suef University
Phase
Phase 2
Overall status
Completed
Start date
February 1, 2023
Completion date
January 30, 2024
Enrollment
140 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostatic hyperplasia